Browse diseases

…onship with all-cause mortality in all patients with or without cirrhosis. Patients with a HbA1c level of 6-7% had the lowest mortality i…

…, monitoring, and treatment needs to be established. Given that MASLD is a multisystem disease, assessing cost effectiveness should c…

…developing cirrhosis, HCC and mortality. Alongside treatment of haemochromatosis, it is crucial for healthcare professionals to evaluate and act…

…Introduction Cirrhosis is often diagnosed late, limiting opportunities for surveillanc…

…2026-ABS-0285 Figure 2). In women without cirrhosis, the annual HCC incidence was 0.01% for HBsAg loss ≤50 years, 0.06% for 51 - 60…

…testinal barrier dysfunction in cirrhosis using an experimental cirrhosis model and patient-derived intestinal biopsies.Design We develop…

… (p=0.046).Conclusion Patients without or with cirrhosis due to MASLD treated with resmetirom experience sustained improvement in sel…

…lance guidance highlighting that early treatment of varices and hepatocellular carcinoma (HCC) reduces morbidity and mortality. We hypothesised that the…

…Cirrhosis is the end-stage of chronic liver disease and clinically can ma…

…inistrative burdens on clinical staff. The increasing number of cirrhosis patients in Chester requiring ongoing care underscores the need…

…tudies and case series raised concerns about decreased rates of de novo HCC following DAA therapy, particularly in patients with advanced c…

…to 0.32) and HCC (HR 0.03, 95% CI 0.01 to 0.21) in Group 1, and cirrhosis (HR 0.50, 95% CI 0.41 to 0.61) and HCC (HR 0.25, 95% CI 0.16 to…